Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Condition(s):NF1; Cutaneous Neurofibroma; MonotherapyLast Updated:February 29, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):NF1; Cutaneous Neurofibroma; MonotherapyLast Updated:February 29, 2024Recruiting
Condition(s):Neurofibromatosis 1, NF1Last Updated:October 6, 2015Completed
Condition(s):Neurofibromatosis 1Last Updated:April 24, 2019Completed
Condition(s):Neurofibromatosis 1; ScoliosisLast Updated:November 1, 2019Completed
Condition(s):Neurofibromatosis 1Last Updated:February 5, 2024Recruiting
Condition(s):Neurofibromatosis 1Last Updated:November 22, 2016Completed
Condition(s):Autism Spectrum Disorder; Neurofibromatosis 1Last Updated:April 2, 2021Completed
Condition(s):Neurofibromatosis 1; Plexiform NeurofibromasLast Updated:February 22, 2024Recruiting
Condition(s):Neurofibromatosis 1Last Updated:July 12, 2023Recruiting
Condition(s):Neurofibromatosis Type 1Last Updated:November 28, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.